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Abstract  
HIV/AIDS continues to spread worldwide, and most of the HIV-infected people living in 
developing countries have little or no access to highly active antiretroviral therapy. The 
development of efficient and low-cost microbicides to prevent sexual transmission of HIV 
should be given high priority because there is no vaccine available yet. Cyanovirin-N (CVN) 
is an entry inhibitor of HIV and many other viruses, and it represents a new generation of 
microbicide that has specific and potent activity, a different mechanism of action and unusual 
chemicophysical stability. In vitro and in vivo antiviral tests suggested that the anti-HIV effect 
of CVN is stronger than a well-known gp120-targeted antibody (2G12) and another 
microbicide candidate, PRO2000. CVN is a cyanobacteria-derived protein that has special 
structural features, making the artificial production of this protein very difficult. In order to 
develop an efficient and relatively low cost approach for large scale production of 
recombinant CVN to satisfy medical use, this protein has been expressed in many systems by 
trial-and-error. Here, to summarize the potential, and remaining challenges, for the 
development of this protein into an HIV prevention agent, the progress in the structural 
mechanism determination, heterologous production, and pharmacological evaluation of CVN 
is reviewed. 
Keywords: Human immunodeficiency virus; microbicide; Cyanovirin-N; gp120 binding; 
pharmacological evaluation; heterologous production; 
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Introduction 
Human immunodeficiency virus (HIV) remains a global health problem of unprecedented 
dimensions. Globally, there are an estimated 33 million people living with HIV (UNAIDS 
2008). The continuing HIV epidemic highlights the urgent need for additional effective 
methods of prevention. Major efforts have been focused on developing vaccines, but the high 
genetic variability of HIV makes this approach very difficult, and protection remains elusive 
(Cohen 2009). While condoms are highly effective at preventing HIV transmission, they are a 
contraceptive that requires partner consent and consequently are not an available option for 
many women at risk of HIV infection (Shattock et al. 2004). Thus, new prevention approaches 
that can be initiated (controlled) by women are desperately needed. One solution is the 
development of topical microbicides that can be applied vaginally (and possibly rectally) to 
prevent HIV transmission (Grant et al. 2008). A broad range of compounds, including specific 
entry inhibitors of viral envelope or cellular receptors, are currently in development as 
microbicide candidates (Balzarini and Van Damme. 2007). Cyanovirin-N (CVN), an entry 
inhibitor of HIV that was initially isolated from the cyanobacterium Nostoc ellipsosporum 
(Boyd et al. 1997), represents a new generation of microbicides due to its specific and potent 
activity, different mechanism of action and unusual chemicophysical stability. In vivo studies 
with CVN formulated as a gel have shown promising efficacy as a microbicide candidate. In 
addition, a recent ex vivo test showed that the antiviral effect of CVN is stronger than that of 
PRO 2000  (Fischetti et al. 2009; Huskens et al. 2009), a non-specific polyanion microbicide. 
The greater activity and specificity of CVN may provide a more effective next generation 
approach to microbicide development. In addition to properly evaluating its pharmacological 
action, another formidable challenge for the development of CVN is how to produce 
biologically active recombinant CVN (rCVN) on a large scale with the relatively low cost 
necessary to satisfy medical use. In this review, we summarize the general knowledge as well 
as the potential application of CVN, and then focus on the advances in large-scale production. 
Structural characteristics of CVN 
CVN has a unique sequence of 101 amino acid residues (Boyd et al. 1997). Although the two 
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halves (residues 1-50 and 51-101) in CVN share a high degree of sequence homology, CVN 
has an extremely low sequence homology with any other known protein. It has no homology 
greater than 8 contiguous amino acids or 20% of the total sequence to any other known protein. 
In addition, this protein contains four cysteines that form two intramolecular disulfide bonds. 
Disruption of these disulfide bonds results in the loss of CVN’s anti-HIV activity (Bewley et 
al. 1998; Yang et al. 1999). The disulfide bonds and lack of sequence homology makes the 
artificial production of this protein very difficult.  
At this point in time, the structure of CVN and its mutants have been solved a total of 23 times 
using crystallography or NMR (Protein Data Bank, http://www.rcsb.org/pdb/home/home.do). 
The protein displays an internal two-fold pseudosymmetry, and the two repeat sequences do 
not form separate domains (Bewley et al. 1998). Wild type (WT) CVN is a monomer in 
solution and exhibits a domain-swapped dimer in the crystal form (Fig. 1A) (Barrientos et al. 
2002). The monomer is comprised of two independent carbohydrate binding sites that 
individually bind to di- and tri-mannoses [Fig. 1B] of the gp120 protein of HIV-1 with an 
affinity that is stronger than that of the broadly neutralizing anti-HIV-1 antibody 2G12, 
another gp120-targeting entry inhibitor (Botos et al. 2002). High-affinity binding through 
multivalent binding sites on CVN and clustered oligomannosides on gp120 is essential 
for CVN’s antiviral activity. Mutants containing two or more binding sites are functional at 
low nanomolar concentrations. Monovalent, monomeric mutants of CVN are inactive in 
inhibiting viral entry, and bind gp120 with greatly reduced affinity. Constructs containing a 
single carbohydrate-binding domain that are capable of forming domain swapped dimmers are 
also functional (Liu et al. 2009). Owing to its special sequence and 3D structure, CVN is 
insensitive to denaturants, detergents, organic solvents, and extreme temperatures. These 
features strengthen its potential as a microbicide, as well as providing a simple heat 
precipitation process to separate it from other host proteins when it is expressed in 
heterologous bacteria or cells. 
Production of CVN in heterologous hosts 
The production of recombinant proteins in a highly purified and well-characterized form has 
become a major part of the pharmaceutical biotechnologists job (Terpe 2006). As a promising 
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microbicide candidate, a 5 mg dose of CVN, which proved to be effective in macaque studies, 
requires a production capacity of 5000 kg a year to supply twice weekly doses for just 10 
million women (Shattock et al. 2003). This scale of protein production may be achievable only 
by an expression system that could produce rCVN with high efficiency and low cost.   
Expression rCVN in E. coli and other commensal bacteria 
Escherichia coli (E. coli) is the most widely used organisms for r-protein production because 
of its profound genetic and physiological characterization, its short generation time, the ease 
of handling, the established fermentation know-how and finally its high specific productivity. 
As a monomeric protein with 2 essential disulfide-bonds and no glycosylation, the initial 
heterologous expression of CVN was performed in the periplasmic space of E. coli. Boyd et al 
synthesized a sequence coding for the FLAG-CVN fusion, and succeeded in expressing it in E. 
coli. However, the product was a mixture of a series CVN derivatives, including intact protein, 
truncated protein and ompA fused proteins that decreased its anti-HIV potency and purity. 
Substitution of the ompA signal peptide with the pelB sequence resulted in intact rCVN, but 
this expression system yielded only 10 mg target protein per liter of culture (Boyd et al. 1997). 
In addition, the purification process based on HPLC could not meet the requirement of activity 
determination and other large scale operations. The low yield of CVN from the periplasmic 
space is due to its special sequence and membrane structure, the low chaperone and foldase 
level and the high periplasmatic protease concentration in the host cell. The secretion systems 
of E. coli result in comparably low product yields, making them only suitable for compounds 
marketed in small quantities, like orphan drugs.   
To increase the yield of CVN, inclusion body (IB) expression in the cytoplasm of E. coli was 
attempted (Colleluori et al. 2005). Following refolding by a conventional process and 
purification by ion exchange chromatography, about 40 mg/L of rCVN was produced in 
shaking flask culture, and 140 mg/40 g wet cell/L for fed batch high-cell-density culture. This 
is the highest yield of rCVN reported to date. Unfortunately, the final product is a mixture of 
full-length monomeric and dimeric rCVN native protein, and 1 or 4 N-terminal residues 
deleted isomers. The heterogeneity of rCVN from IB exposes the weakness of this type of 
expression. Several vectors to express CVN directly in E. coli were also tried, but the low 
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yield and IB formation were disappointing. Finally, we turned our attention to the chaperon 
fused expression system. Fortunately, this system with a hexahistidine and small 
ubiquitin-related modifier (SUMO) double-tagged CVN lead to a soluble fusion protein in the 
cytoplasm of E. coli at a level of >30% of the total soluble protein (TSP). With this construct, 
intact and native rCVN can be rapidly purified in a soluble and biologically active form by 2 
rounds of affinity chromatography with one round of SUMO protease digestion in between 
(Gao et al. 2009). In a 30 L bioreactor using conventional fed-batch culture (FBC), more than 
100 mg/L native rCVN was afforded (unpublished data). An N-terminal extended CVN 
derivative was also constructed and expressed using the same strategy. This CVN derivative 
displayed higher activity on cell viability and in a cell-to-cell fusion assay, as well as lower 
cytotoxicity. Furthermore, the yield of this CVN derivative under the same FBC conditions 
was approximately 170±10 mg/L (unpublished data). The higher yield of this CVN derivative 
did not result from higher expression in the cytoplasm of E. coli, but is due to the extended 
sequence on the N-terminal of CVN acting as a bridge between the SUMO and CVN, and thus 
facilitates the digestion by SUMO protease. Overexpression of soluble SUMO-CVN in the 
cytoplasm of E. coli to obtain intact, homogeneous, and monomeric rCVN by simple 
downstream processes, makes this system promising for practical applications. 
CVN was also expressed in commensal Streptococcus gordonii either as excreted protein or 
attached to the bacterial cell surface. As an excreted protein, it was able to bind HIV-1 and 
when it was bound to the bacterium, it was able to capture HIV-1 (Giomarelli et al. 2002). 
Other work has demonstrated the utility of Lactobacillus jensenii as agents of mucosal drug 
delivery to secrete CVN. This recombinant lactobacillus bacterium has been shown to produce 
high levels of structurally intact r-protein, exhibiting potent antiviral activity against 
laboratory and primary HIV-1 isolates. For example, the 50% inhibitory concentration of this 
lactobacillus-derived CVN to CCR5-tropic HIVBaL is only 0.3 nM (Liu et al. 2006). The 
development of a novel, live microbicide that employs a commensal bacteria to deliver CVN 
to the vaginal channel is another fascinating application of CVN (Ndesendo et al. 2008). 
In eukaryotic host 
Pichia pastoris (P. pastoris) is an alternative host that, like E. coli, can be grown cheaply and 
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rapidly, possesses certain posttranslational modification pathways, is able to secrete 
more efficiently and permits the production of r-proteins without intense process development. 
Introduction of the coding sequence for CVNs into P. pastoris demonstrate the potential for 
expression of rCVN in a eukaryotic system. Unfortunately, it is difficult to obtain native 
rCVN with this system because of high-mannose N-glycosylation at position N30 and P51 
mediated dimerization of the final product in the hinge region, both of which result in a loss of 
antiviral activity of rCVN (Mori et al. 2002). Furthermore, the yield in P. pastoris was only 10 
mg/L, which is very low compared with cytoplasmic expression in E. coli.  
A more feasible eukaryotic system to express CVN is a transgenic plant. The yield is 
approximately 130 μg/g from fresh leaves of the total plant, and 0.635±0.298 mg/L in a 
24d-cultured rhizosecretion system. A bioactivity assay proved that the tobacco synthesized 
CVN is almost all in the monomeric form (Sexton et al. 2006). Under optimized conditions, 
the yield of the rhizosecretion culture of CVN is 3.2 mg/L, or 766 μg/g root dry weight/24 h. 
This is the highest reported yield for rhizosecretion of a heterologous protein. None the less, 
for commercial viability, extensive optimization should still be undertaken to further increase 
the yield of rCVN in this transgenic system (Colgan et al. 2009; Drake et al. 2009). After the 
successful expression rCVN in a transgenic plant, a fusion protein of CVN and 
HIV-neutralizing mAb b12 was also produced in this transgenic plant. It was demonstrated 
that each moiety of the fusion protein retained its binding ability to gp120, and that this fusion 
protein exhibited increased anti-HIV potency compared to b12 or CVN alone (Sexton et al. 
2009). Thus, production of rCVN from a transgenic plant may be a new approach for the 
microbicide manufacturing, although the undeveloped down-stream processes, potential 
post-translational modifications, and the higher cost and lower yield compared to that of E. 
coli make it non-viable now for meeting the emergency of the HIV epidemic. 
In conclusion, CVN, a promising microbicide candidate with a special primary structure that 
is sensitive to disulphide bond formation and side-chain modification, has been expressed in E. 
coli, yeast and a transgenic plant (Table 1). The transgenic plant system is the most 
sophisticated, and represents the future of production of this drug candidate. At this moment 
though, the soluble expression in the cytoplasm of E. coli might be the only feasible option.  
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Antiviral activity and a pre-clinical study of CVN as a microbicide 
Antiviral activities and drug targets of CVN 
CVN was initially isolated as part of a screening program searching for naturally occurring 
virucidal agents that could be developed into anti-HIV microbicides. It irreversibly inactivates 
a broad range of immunodeficiency viruses such as T-tropic, M-tropic and dual tropic primary 
clinical isolates of HIV, many T-tropic laboratory strains of HIV-1, HIV-2, simian 
immunodeficiency virus, and feline immunodeficiency virus (Boyd et al. 1997). As a potent 
virucidal protein, CVN is effective against most HIV strains with an EC50 of less than 1 nM 
and a CC50 greater than 400 nM (Table 2). The antiviral activity of CVN includes direct 
virucidal efficacy, inhibition of cell-to-cell fusion, virus-to-cell fusion and cell-to-cell 
transmission. Preventing of the fusion and transmission of HIV-1 between infected and 
uninfected cells might greatly contribute to the potency of CVN against HIV(Dey et al. 2000). 
The potent HIV-inactivation ability of CVN makes this protein of particular interest in the 
development of a microbicide that would be the first line of defense in preventing the sexual 
transmission of HIV. Since the entry inhibitor Enfuvirtide (T-20) has been approved by Food 
and Drug Administration, and been shown to constitute an important category of anti-HIV 
drugs, CVN, a potent fusion inhibitor, also might be developed into a therapeutic compound 
against HIV-1if its potential mitogenicity and immunogenicity were attenuated or eliminated 
by means of PEGlation or other modification (Zappe et al. 2008). Another interesting 
application of CVN is its potential use as a targeting agent. A fusion protein consisting of 
CVN and Pseudomonas exotoxin PE38 showed enhanced cytotoxicity to HIV-infected 
gp120-expressing H9 cells, raising the possibility that HIV infected cells could be targeted 
with these chimeric molecules (Mori et al. 1997).  
The carbohydrate moiety of gp120 consists of 24 N-linked oligosaccharides, among which 11 
are believed to be high-mannose or hybrid type, and 13 are complex type. CVN exerts its 
activity by binding to high-mannose oligosaccharides, located predominantly in the C2-C4 
region of gp120, and prevents the virus entry by blocking fusion with the cell membrane and 
cell-to-cell transmission (Hu et al. 2007; Shenoy et al. 2001). The 1.35 A high-resolution 
structure of P51G-m4-CVN suggests that the Arg-76 and Glu-41 residues of CVN are critical 
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components for the high mannose specificity and affinity. Upon binding to gp120, Arg-76 
undergoes a large conformational change, bringing its side chain from an unlocked position to 
a locked position, in which two direct hydrogen bonds to the ligand are formed. Glu-41 may 
contribute to the tight binding of the sugar and possibly in the selectivity for Manα(1-2)Manα 
(Fromme et al. 2008). Recently, molecular-dynamics simulations in solution demonstrated no 
conformational preferences for Arg-76. Instead, there is a very stable eight-hydrogen-bond 
network between the di-mannose ligand in gp120 and the predominant main-chain atoms in 
CVN (Vorontsov et al. 2009). Thus, the mutual interaction between CVN and gp120 might 
contribute simultaneously to their high affinity and specificity. This mechanism provides 
guidance for the microbicide development of CVN, as well as for the design of CVN 
derivatives with enhanced antiviral activity. 
In addition to immunodeficiency viruses, CVN is also effective against Ebola virus, influenza 
A and B, hepatitis C virus, measles virus, herpes simplex virus type-1 (HSV-1) and HSV-6 
(Balzarini 2007; Buffa et al. 2009; Helle et al. 2006; O'Keefe et al. 2003). The mutual feature 
of the viruses that are sensitive to CVN is that of N-linked high-mannose oligosaccharides on 
the surface glycoprotein, which constitute the unique binding sites for CVN (Barrientos et al. 
2006). In a similar fashion to its effect on HIV, CVN not only blocks the entry of HSV-1 to 
target cells, but is also capable of significantly inhibiting membrane fusion mediated by HSV 
glycoproteins (Tiwari et al. 2009). The potent inhibitory activity of CVN against HSV-1 and 
other viruses suggests that this protein can be used not only for a topical microbicide against 
HIV-1, but also for the development of a broad-spectrum antiviral reagent for other enveloped 
viruses.  
Preclinical test of CVN against HIV 
In vivo studies with CVN formulated as a gel, have shown promising protection against male 
or female macaques (Macaca fascicularis) rectal or vaginal challenged with the highly 
pathogenic SHIV89.6P virus. Furthermore, CVN produced no cytotoxicity or clinical adverse 
effects in neither the in vitro nor in vivo model (Tsai et al. 2004; Tsai et al. 2003). Because the 
efficacy of a topical microbicides might be weakened by the dilution or neutralization of the 
vaginal fluid, semen, and personal sanitation habits, or interfered by the commensal bacteria, 
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in vitro and ex vivo models of female genital tissue explants were established to evaluate these 
impacts (Buffa et al. 2009). It was demonstrated that the potent activity of CVN remained in 
low nanomolar range in the presence of whole semen and was minimally impacted by the 
presence of Candida albicans. Furthermore, CVN potently inhibited infection of ectocervical 
explants and virus dissemination by tissue-emigrating cells.  
In another preclinical test, CVN and two other microbicide candidates currently in clinical 
trials, i.e., PRO 2000 and PMPA gel (tenofovir), were evaluated in a novel penile tissue 
explant model (Fischetti et al. 2009). It was found that CVN conferred 95% protection against 
HIV-1 at 11 μg/ml, which is similar to that seen in cervical explants and is a dose 1/500 of that 
shown to be protective in macaques. As a control, the dose for PRO2000 to confer total 
protection was 10 times greater than that of CVN, and for PMPA, the dose was almost 100 
times higher. The ability to block HIV-1 transfer by migratory cells is in agreement with the 
ability of CVN to weaken dendritic cell specific HIV-1 transmission in vitro. CVN was not 
toxic for male or female genital tissue explants, but a degree of cytokine upregulation 
following 2 h exposure to CVN, was observed. Together, these studies suggest that CVN is a 
good candidate for further testing in non-human-primates followed by human clinical trials, 
although the potential mitogenic properties of CVN raise some concern about its safety. 
Comparison between CVN and other lectin-based candidates 
In addition to CVN, several lectins also exhibit significant activity against HIV and other 
enveloped viruses. So far, the most promising lectin-based anti-HIV candidates are CVN, 
scytovirin (SVN), Microcystis viridis lectin (MVL), and griffithsin (GRFT), all of which are 
found in algae. CVN and SVN take only nanomoles to inhibit half of the HIV virus in vitro 
and the inhibitory activity of GRFT is even stronger, with an EC50 2/5 of that of CVN. GRFT 
possesses no measurable lymphoprolifreation activity and is probably a safer candidate. 
However, the chemical and physical stability of GRFT is not as well as that of CVN and its 
antiviral effect and safety remain to be evaluated in transmission animal models. Different 
from most of other candidates, CVN binds strongly with glycoproteins having Man8 or Man9, 
regardless of the number of glycans on a glycoprotein, accounting for its strong antiviral 
activity. Actinohivin (AH), a lectin found in a cultured actinomyete, has showed more specific 
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affinity to gp120 because, unlike CVN, it could not bind with a single High-mannose type 
glycan, and thus might be less toxic (Tanaka et al. 2009). Although CVN may cause side 
effects such as cytotoxicity and mitogenic activity, it has been proved effective and safe in 
vaginal and rectal transmission models. Large-scale production is another important issue in 
microbisides development and remains to be a challenge for lectins. Great advantages have 
been made in large-scale production of CVN with low cost, whereas efficient expression of 
GRFT has recently proved successful only in transgenic plant, with a yield of up to 300mg/Kg 
leaf (O'Keefe et al. 2009). Continuous advances in research provide more choices for the 
development of lectin microbicides, and CVN owns its advantages to be a promising 
candidate. 
Conclusions and Perspectives 
Results from clinical trial on large-scale HIV prevention have been disappointing for the first 
generation of microbicide candidates, such as Buffergel, Carraguard, SAVVY, PRO2000 etc 
(Morris and Lacey. 2010). CVN is a promising microbicide candidate that was discovered 12 
years ago and has been thoroughly tested in different assay and pharmacological models. It 
has displayed an impressive potential as a microbicides, and could even be a targeting reagent. 
Using the present technology, it may be possible to produce CVN on large scale and at low 
cost. The soluble cytoplasm expression of native rCVN, plus the established know-how of the 
bioprocesses of E. coli-produced biologics in the industrial sector, might provide a ready 
solution for the manufacture of this microbicide candidate. Other sophisticated approaches 
provide a backup for future manufacturing of the drug. Progress in structural mechanism 
investigation, pharmacological evaluation and heterologous production of CVN, and the 
breakthrough in population studies of other microbicides confer a potential on CVN. In 
addition, the promising progress of a HIV vaccine (Cohen 2009) highlighted the possibility to 
build a combinational program including microbicides, vaccines, and/or pre-exposure 
prophylaxis, as well as behavioral science interventions for more effective HIV-1 prevention. 
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Table 1 Compilation of the key features of recombinant CVN from various expression systems 
Expression 
type 
Purification process and yield Key features References
Blue alga Nostoc ellipsosporum 
Natural 
product 
Solvent extraction and 
precipitation, RP-HPLC. Yield 
not determined. 






Anti-Flag AC, RP-VLC and 
RP-HPLC. Yield <10 mg/L 
Soluble expression of Flag fused and native 
rCVN. Flag fusion decreased its activity, while 
native rCVN was a mixture of intact and 
truncated forms of CVN.  




RP-VLC, RP-HPLC. Yield 
approximately 10 mg/L 
Soluble expression of homogeneous full-length 
rCVN under the lead of the pelB signal. 




Ni-NTA AC, RP-HPLC. Yield 
10 mg/L (optimal conditions). 
Homogeneous C-terminal pentahistidine fused 
rCVN and its Asn30 and/or Pro51 substituted 
mutants. 




Inclusion body refolding, IEC. 
Yield 40 mg/L for flask 
shaking. 140 mg/40 g wet cell/L 
culture for FB-HCDC. 
High yield. Inclusion body. Heterologous final 
product of monomeric and dimeric rCVN of 
full-length native protein, and 1 or 4 






Ni-NTA AC, SUMO protease 
cleavage. Yield 3-4 mg/g wet 
cell, 30% of the TSP. 
Soluble expression in the cytoplasm of E. coli. 
Simplified purification process and high yield. 
Obtained intact and homogeneous native rCVN 
from the His-SUMO-CVN fusion. 





Ni-NTA AC. Yield 10 mg/L 
(un-optimized condition) 
Ex-secreted expression of C-terminal 
pentahistidine fused CVN. N-glycosylated into 
an inactive form and conformational 
heterogeneity for WT rCVN, but CVN P51G 
mutant exhibited comparable activity and 
stability. 






Only detected by WB analysis. 
Yield in plant: 130 ng/mg from 
the fresh leaf, 0.85% of TSP.  
yield for rhizosecretion: 
0.635±0.298 μg/mL after 24 
days culture 
Soluble expression, the yield is higher than 
reported IgGs in transgenic tobacco. Almost 
monomeric form. Tobacco contains a high 
content of toxic alkaloids. Restricted by 
downstream process and NDA regulation for 
the transgenic plant produced rCVN. 
(Sexton et 
al. 2006) 
RP-HPLC, reverse phase - high performance liquid chromatography; VLC, vacuum liquid chromatography; 
AC, affinity chromatography; IEC, ion exchange chromatography; FB, fed-batch; HCDC, high cell density 
culture; SUMO: small ubiquitin-related modifier; WB, western blot 
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Table 2 Antiviral activity of CVN against primary and laboratory HIV strains in cellular assay. Data were 
extracted from the data base of National Institute of Allergy and Infectious Diseases (NIAID) 
(http://www3.niaid.nih.gov/), accessed on the 17th November 2009 from the webpage of 
http://chemdb.niaid.nih.gov/struct_search/misc/invitro.asp?aids=045707. 
 
HIV strain type Cell type 
EC50 CC50 
TI HIV strain type Cell type 
EC50 CC50
TI 
(μM) (μM) (μM) (μM)
HIV-1(RF) CEM-SS  0.0001  > 0.4  > 4000 HIV-1(VIHU) PBL  0.0055  > 0.4 > 72.73 
HIV-1(RF) U-937  0.0005  > 0.4  > 800 HIV-2(ROD) CEM-SS  0.0076  > 0.4 > 52.63 
HIV-1(IIIB) CEM-SS  0.00016  > 0.4  > 2500 HIV-1(G910-6) MT-2  0.0058  > 0.4 > 68.97 
HIV-1(IIIB) MT-2  0.0004  > 0.4  > 1000 HIV-1(WEJO) PBL  0.0067  > 0.4 > 59.7 
HIV-1(IIIB) CEM-SS  0.0004  > 0.4  > 1000 HIV-1(89.6) PBL  0.0073  > 0.4 > 54.79 
HIV-1(214) CEM-SS  0.0004  > 0.4  > 1000 HIV-1(SLKA)
Primary 
macrophages 
 0.0055  > 0.4 > 72.73 
HIV-1(A17) MT-2  0.0008  > 0.4  > 500 HIV-1(Ba-L)
Primary 
macrophages 
 0.017  > 0.4 > 23.53 
HIV-1(205) CEM-SS  0.0008  > 0.4  > 500 HIV-1(89.6) 
Primary 
macrophages 
 0.0368  > 0.4 > 10.87 
HIV-1(G1) CEM-SS  0.0009  > 0.4  > 444.44 HIV-1(Ada-M)
Primary 
macrophages 
 0.0017  > 0.4 > 235.29 
HIV-1(BAKI) PBL  0.0015  > 0.4  > 266.67 HIV-1(RF) CEM-SS  0.00156   0.23  147  
HIV-1(SK1) CEM-SS  0.0048  > 0.4  > 83.33 HIV-1(NL4-3)
U87(CD4+, 
CCR5+) 
 0.0253  ~ 1  ~ 39.5 
HIV-1(MN) MT-2  0.0023  > 0.4  > 173.91 HIV-1(NL4-3)
U87(CD4+, 
CXCR4+) 
 0.0035  < 1  < 285  
HIV-2(MS) CEM-SS  0.0023  > 0.4  > 173.91 HIV-1(NL4-3)
U87(CD4+, 
CCR5+) 
 0.0253  > 1  > 39.5 
HIV-1(WOME) PBL  0.0043  > 0.4  > 93.02      
EC50, 50% effective concentration. CC50, 50% cytotoxic concentration. TI, treatment index 
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 Fig. 1 Crystal structures of CVN. (A) The domain-swapped dimer of CVN. CVN is a three-dimensional 
domain-swapped dimer in the crystal structures with two primary sites near the hinge region and two 
secondary sites on opposite ends of the dimer. The Figure was extracted from PDB 
(http://www.rcsb.org/pdb/explore/explore.do?structureId=1L5E). (B) The crystal structure of rCVN 
complexed to a synthetic hexamannoside at 2.4-A resolution. The binding interface constitutes two stacked 
α(1-2)-linked mannose rings for hexamannoside with the rest of the saccharide molecules pointing towards 
the solution. The Figure was extracted from PDB 
(http://www.rcsb.org/pdb/explore/explore.do?structureId=3GXY). 
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